JP2014159475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014159475A5 JP2014159475A5 JP2014100193A JP2014100193A JP2014159475A5 JP 2014159475 A5 JP2014159475 A5 JP 2014159475A5 JP 2014100193 A JP2014100193 A JP 2014100193A JP 2014100193 A JP2014100193 A JP 2014100193A JP 2014159475 A5 JP2014159475 A5 JP 2014159475A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- amino
- carbons
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 102000003964 Histone deacetylase Human genes 0.000 claims 8
- 108090000353 Histone deacetylase Proteins 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000003610 charcoal Substances 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 239000013522 chelant Substances 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 239000011701 zinc Substances 0.000 claims 5
- 229910052725 zinc Inorganic materials 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 230000004968 inflammatory condition Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- AEDIXYWIVPYNBI-UHFFFAOYSA-N heptanamide Chemical compound CCCCCCC(N)=O AEDIXYWIVPYNBI-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- UKPBSRBABNKKNR-UHFFFAOYSA-N n-hydroxy-8,8-dipyridin-2-yloct-7-enamide Chemical compound C=1C=CC=NC=1C(=CCCCCCC(=O)NO)C1=CC=CC=N1 UKPBSRBABNKKNR-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- AHNXFUDZSQZNIB-UHFFFAOYSA-N 6-(dipyridin-2-ylamino)-n-hydroxyhexanamide Chemical compound C=1C=CC=NC=1N(CCCCCC(=O)NO)C1=CC=CC=N1 AHNXFUDZSQZNIB-UHFFFAOYSA-N 0.000 claims 1
- QKTORDWLHYWRJF-UHFFFAOYSA-N 7-(dipyridin-2-ylamino)-n-hydroxyheptanamide Chemical compound C=1C=CC=NC=1N(CCCCCCC(=O)NO)C1=CC=CC=N1 QKTORDWLHYWRJF-UHFFFAOYSA-N 0.000 claims 1
- MFRXXGYJNARFDZ-UHFFFAOYSA-N 7-[(4-ethoxypyridin-2-yl)-pyridin-2-ylamino]-n-hydroxyheptanamide Chemical compound CCOC1=CC=NC(N(CCCCCCC(=O)NO)C=2N=CC=CC=2)=C1 MFRXXGYJNARFDZ-UHFFFAOYSA-N 0.000 claims 1
- KRJQCKBCOOIVLV-UHFFFAOYSA-N 7-[[4-(2-chlorophenyl)pyridin-2-yl]-pyridin-2-ylamino]-n-hydroxyheptanamide Chemical compound C=1C(C=2C(=CC=CC=2)Cl)=CC=NC=1N(CCCCCCC(=O)NO)C1=CC=CC=N1 KRJQCKBCOOIVLV-UHFFFAOYSA-N 0.000 claims 1
- GDARYEAXBOYVMF-UHFFFAOYSA-N 7-[[4-(2-fluorophenyl)pyridin-2-yl]-pyridin-2-ylamino]-n-hydroxyheptanamide Chemical compound C=1C(C=2C(=CC=CC=2)F)=CC=NC=1N(CCCCCCC(=O)NO)C1=CC=CC=N1 GDARYEAXBOYVMF-UHFFFAOYSA-N 0.000 claims 1
- BTUMJESSYLLGNP-UHFFFAOYSA-N 7-[[4-(4-aminophenyl)pyridin-2-yl]-pyridin-2-ylamino]-n-hydroxyheptanamide Chemical compound C1=CC(N)=CC=C1C1=CC=NC(N(CCCCCCC(=O)NO)C=2N=CC=CC=2)=C1 BTUMJESSYLLGNP-UHFFFAOYSA-N 0.000 claims 1
- RIBJJSPUNGSHDA-UHFFFAOYSA-N 7-[[4-(4-fluorophenyl)pyridin-2-yl]-pyridin-2-ylamino]-n-hydroxyheptanamide Chemical compound C=1C(C=2C=CC(F)=CC=2)=CC=NC=1N(CCCCCCC(=O)NO)C1=CC=CC=N1 RIBJJSPUNGSHDA-UHFFFAOYSA-N 0.000 claims 1
- VKORRCMVVJGHLB-UHFFFAOYSA-N 7-[[5-(4-fluorophenyl)pyridin-2-yl]-pyridin-2-ylamino]-n-hydroxyheptanamide Chemical compound C=1C=C(C=2C=CC(F)=CC=2)C=NC=1N(CCCCCCC(=O)NO)C1=CC=CC=N1 VKORRCMVVJGHLB-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- PAOWEVKKVQSUGI-UHFFFAOYSA-N N-pyridin-2-ylhept-6-enamide Chemical compound C(CCCCC=C)(=O)NC1=NC=CC=C1 PAOWEVKKVQSUGI-UHFFFAOYSA-N 0.000 claims 1
- 208000004179 Oral Leukoplakia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 claims 1
- 125000002720 diazolyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 210000003780 hair follicle Anatomy 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- CWRRFKAJEFXNCI-UHFFFAOYSA-N n-hydroxy-7-[(4-methoxypyridin-2-yl)-pyridin-2-ylamino]heptanamide Chemical compound COC1=CC=NC(N(CCCCCCC(=O)NO)C=2N=CC=CC=2)=C1 CWRRFKAJEFXNCI-UHFFFAOYSA-N 0.000 claims 1
- PGUBEMISCAEYJC-UHFFFAOYSA-N n-hydroxy-7-[(4-methylpyridin-2-yl)-pyridin-2-ylamino]heptanamide Chemical compound CC1=CC=NC(N(CCCCCCC(=O)NO)C=2N=CC=CC=2)=C1 PGUBEMISCAEYJC-UHFFFAOYSA-N 0.000 claims 1
- HHSNUFVTOCHKST-UHFFFAOYSA-N n-hydroxy-7-[(4-phenylmethoxypyridin-2-yl)-pyridin-2-ylamino]heptanamide Chemical compound C=1C(OCC=2C=CC=CC=2)=CC=NC=1N(CCCCCCC(=O)NO)C1=CC=CC=N1 HHSNUFVTOCHKST-UHFFFAOYSA-N 0.000 claims 1
- QKHNNJBLQYMGKB-UHFFFAOYSA-N n-hydroxy-7-[(4-phenylpyridin-2-yl)-pyridin-2-ylamino]heptanamide Chemical compound C=1C(C=2C=CC=CC=2)=CC=NC=1N(CCCCCCC(=O)NO)C1=CC=CC=N1 QKHNNJBLQYMGKB-UHFFFAOYSA-N 0.000 claims 1
- CMTHCRMWVNPXEE-UHFFFAOYSA-N n-hydroxy-7-[(4-propan-2-yloxypyridin-2-yl)-pyridin-2-ylamino]heptanamide Chemical compound CC(C)OC1=CC=NC(N(CCCCCCC(=O)NO)C=2N=CC=CC=2)=C1 CMTHCRMWVNPXEE-UHFFFAOYSA-N 0.000 claims 1
- XPICHFGZLSEZPN-UHFFFAOYSA-N n-hydroxy-7-[(4-propoxypyridin-2-yl)-pyridin-2-ylamino]heptanamide Chemical compound CCCOC1=CC=NC(N(CCCCCCC(=O)NO)C=2N=CC=CC=2)=C1 XPICHFGZLSEZPN-UHFFFAOYSA-N 0.000 claims 1
- QPUMRJLDXUWBMO-UHFFFAOYSA-N n-hydroxy-7-[(5-methylpyridin-2-yl)-pyridin-2-ylamino]heptanamide Chemical compound N1=CC(C)=CC=C1N(CCCCCCC(=O)NO)C1=CC=CC=N1 QPUMRJLDXUWBMO-UHFFFAOYSA-N 0.000 claims 1
- SQJGJTWESUXCFD-UHFFFAOYSA-N n-hydroxy-7-[(5-phenylmethoxypyridin-2-yl)-pyridin-2-ylamino]heptanamide Chemical compound C=1C=C(OCC=2C=CC=CC=2)C=NC=1N(CCCCCCC(=O)NO)C1=CC=CC=N1 SQJGJTWESUXCFD-UHFFFAOYSA-N 0.000 claims 1
- YGWRFDHAWXAETA-UHFFFAOYSA-N n-hydroxy-7-[[4-(2-methylphenyl)pyridin-2-yl]-pyridin-2-ylamino]heptanamide Chemical compound CC1=CC=CC=C1C1=CC=NC(N(CCCCCCC(=O)NO)C=2N=CC=CC=2)=C1 YGWRFDHAWXAETA-UHFFFAOYSA-N 0.000 claims 1
- RFRLEMKVULQTAB-UHFFFAOYSA-N n-hydroxy-7-[[4-(3-methylphenyl)pyridin-2-yl]-pyridin-2-ylamino]heptanamide Chemical compound CC1=CC=CC(C=2C=C(N=CC=2)N(CCCCCCC(=O)NO)C=2N=CC=CC=2)=C1 RFRLEMKVULQTAB-UHFFFAOYSA-N 0.000 claims 1
- OOGGMRCLBZUBPO-UHFFFAOYSA-N n-hydroxy-7-[[4-(4-methylphenyl)pyridin-2-yl]-pyridin-2-ylamino]heptanamide Chemical compound C1=CC(C)=CC=C1C1=CC=NC(N(CCCCCCC(=O)NO)C=2N=CC=CC=2)=C1 OOGGMRCLBZUBPO-UHFFFAOYSA-N 0.000 claims 1
- FTDWUSJBYXAFEJ-UHFFFAOYSA-N n-hydroxy-7-[isoquinolin-3-yl(pyridin-2-yl)amino]heptanamide Chemical compound C=1C2=CC=CC=C2C=NC=1N(CCCCCCC(=O)NO)C1=CC=CC=N1 FTDWUSJBYXAFEJ-UHFFFAOYSA-N 0.000 claims 1
- AOBJFQAKCMEONB-UHFFFAOYSA-N n-hydroxy-7-[pyridin-2-yl(pyridin-3-yl)amino]heptanamide Chemical compound C=1C=CC=NC=1N(CCCCCCC(=O)NO)C1=CC=CN=C1 AOBJFQAKCMEONB-UHFFFAOYSA-N 0.000 claims 1
- JMWOJCWEYBYEOY-UHFFFAOYSA-N n-hydroxy-7-[pyridin-2-yl(quinolin-2-yl)amino]heptanamide Chemical compound C=1C=C2C=CC=CC2=NC=1N(CCCCCCC(=O)NO)C1=CC=CC=N1 JMWOJCWEYBYEOY-UHFFFAOYSA-N 0.000 claims 1
- 201000008557 oral mucosa leukoplakia Diseases 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- -1 troches Substances 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0901406A GB0901406D0 (en) | 2009-01-28 | 2009-01-28 | Novel compounds |
| GB0901406.9 | 2009-01-28 | ||
| GB0912383A GB0912383D0 (en) | 2009-07-16 | 2009-07-16 | Novel compounds |
| GB0912383.7 | 2009-07-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546968A Division JP5597649B2 (ja) | 2009-01-28 | 2010-01-26 | スクリプタイドアイソスター（ｓｃｒｉｐｔａｉｄｉｓｏｓｔｅｒｅｓ）およびその治療における使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014159475A JP2014159475A (ja) | 2014-09-04 |
| JP2014159475A5 true JP2014159475A5 (enExample) | 2014-10-16 |
| JP5981956B2 JP5981956B2 (ja) | 2016-08-31 |
Family
ID=42102264
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546968A Expired - Fee Related JP5597649B2 (ja) | 2009-01-28 | 2010-01-26 | スクリプタイドアイソスター（ｓｃｒｉｐｔａｉｄｉｓｏｓｔｅｒｅｓ）およびその治療における使用 |
| JP2014100193A Expired - Fee Related JP5981956B2 (ja) | 2009-01-28 | 2014-05-14 | スクリプタイドアイソスター（ｓｃｒｉｐｔａｉｄｉｓｏｓｔｅｒｅｓ）およびその治療における使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546968A Expired - Fee Related JP5597649B2 (ja) | 2009-01-28 | 2010-01-26 | スクリプタイドアイソスター（ｓｃｒｉｐｔａｉｄｉｓｏｓｔｅｒｅｓ）およびその治療における使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8748458B2 (enExample) |
| EP (1) | EP2391605B1 (enExample) |
| JP (2) | JP5597649B2 (enExample) |
| CN (2) | CN102333761B (enExample) |
| CA (1) | CA2750086C (enExample) |
| ES (1) | ES2650810T3 (enExample) |
| IL (1) | IL214244A (enExample) |
| MX (1) | MX2011007864A (enExample) |
| WO (1) | WO2010086646A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2391605B1 (en) * | 2009-01-28 | 2017-11-08 | Karus Therapeutics Limited | Scriptaid isosteres and their use in therapy |
| ES2647368T3 (es) | 2010-10-08 | 2017-12-21 | Vib Vzw | Inhibidores de HDAC para tratar la enfermedad de Charcot-Marie-Tooth |
| EP2508510A1 (en) | 2011-04-06 | 2012-10-10 | Ikerchem, S.L. | Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof |
| KR101415742B1 (ko) * | 2011-12-21 | 2014-07-04 | 영남대학교 산학협력단 | 6―아미노피리딘―3―올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물 |
| US9889139B2 (en) | 2011-12-21 | 2018-02-13 | Research Cooperation Foundation Of Yeungnam University | Method of treating inflammatory bowel disease comprising administering a pharmaceutical composition comprising a 6-aminopyridin-3-ol compound or a pharmaceutically acceptable salt thereof as an active ingredient to a subject |
| US9676765B2 (en) | 2012-11-07 | 2017-06-13 | Karus Therapeutics Limited | Histone deacetylase inhibitors and their use in therapy |
| US20160052926A1 (en) * | 2013-03-15 | 2016-02-25 | Hutchison Medipharma Limited | Novel pyrimidine and pyridine compounds and usage thereof |
| WO2014153280A1 (en) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| NZ714283A (en) * | 2013-05-10 | 2020-04-24 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
| GB201419228D0 (en) * | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419264D0 (en) * | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4792562A (en) | 1985-12-04 | 1988-12-20 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyrrol-1-yl)pyridinamines having memory enhancing activity |
| JPH0532662A (ja) | 1990-11-09 | 1993-02-09 | Nissan Chem Ind Ltd | 置換ピラゾール誘導体および農園芸用殺菌剤 |
| US5214038A (en) | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| JP2000511883A (ja) | 1996-04-19 | 2000-09-12 | ノボ ノルディスク アクティーゼルスカブ | ホスホチロシン認識ユニットを有する分子のモジュレーター |
| EP0887348A1 (en) * | 1997-06-25 | 1998-12-30 | Boehringer Mannheim Italia S.p.A. | Bis-Indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them |
| JP3712529B2 (ja) * | 1998-04-24 | 2005-11-02 | 大鵬薬品工業株式会社 | ３，３−ジピリジルアクリル酸アミド誘導体又はその薬学的に許容される塩 |
| GB9929988D0 (en) * | 1999-12-17 | 2000-02-09 | Celltech Therapeutics Ltd | Chemical compounds |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| ES2322950T3 (es) | 2002-03-13 | 2009-07-02 | Janssen Pharmaceutica Nv | Derivados de aminocarbonilo como nuevos inhibidores de histona-desacetilasa. |
| JP4235726B2 (ja) | 2002-11-19 | 2009-03-11 | 国立大学法人 奈良先端科学技術大学院大学 | 大きな二光子吸収特性を示すアセチレン結合により連結されたビス（イミダゾリルポルフィリン金属錯体）を構成単位とするポルフィリン連鎖体及びその製造方法 |
| AU2003900608A0 (en) * | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
| EP1599449A2 (en) * | 2003-02-25 | 2005-11-30 | TopoTarget UK Limited | Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors |
| US20090110720A1 (en) | 2004-10-06 | 2009-04-30 | Anders Nykjaer | Use of compounds for the prevention of drug-induced cell toxicity |
| JP2008530136A (ja) | 2005-02-14 | 2008-08-07 | ミイカナ セラピューティクス インコーポレイテッド | ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物 |
| TW200716545A (en) | 2005-06-10 | 2007-05-01 | Sigma Tau Ind Farmaceuti | Indole derivatives having anti-tumor activity |
| WO2007050348A2 (en) * | 2005-10-21 | 2007-05-03 | Merck & Co., Inc. | Potassium channel inhibitors |
| WO2007085540A1 (en) | 2006-01-27 | 2007-08-02 | Glaxo Group Limited | 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives |
| WO2008007780A1 (fr) * | 2006-07-13 | 2008-01-17 | Kyowa Hakko Kirin Co., Ltd. | Dérivé du pentadiènamide |
| CN101534831B (zh) * | 2006-09-11 | 2013-07-17 | 柯瑞斯公司 | 包含锌结合基团的取代的酪氨酸抑制剂 |
| ES2532899T3 (es) * | 2006-10-28 | 2015-04-01 | Methylgene Inc. | Derivados de dibenzo[b,f][1,4]oxazepina como inhibidores de histona desacetilasa |
| JP5178731B2 (ja) | 2006-11-22 | 2013-04-10 | カルス セラピューティクス リミテッド | デプシペプチドおよびその治療的使用 |
| WO2008139987A1 (ja) * | 2007-04-26 | 2008-11-20 | Japan Science And Technology Agency | Ｇタンパク質共役型レセプタ－作動剤 |
| WO2009003240A1 (en) | 2007-07-03 | 2009-01-08 | Commonwealth Scientific And Industrial Research Organisation | Iron control in leaching |
| WO2009137462A2 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| EP2391605B1 (en) * | 2009-01-28 | 2017-11-08 | Karus Therapeutics Limited | Scriptaid isosteres and their use in therapy |
| CA2825599C (en) | 2011-02-01 | 2021-07-13 | The Board Of Trustees Of The University Of Illinois | 4-methyl-n-hydroxybenzamide compounds as histone deacetylase (hdac) inhibitors |
| CA2850757A1 (en) | 2011-10-03 | 2013-04-11 | The Trustees Of Columbia University In The City Of New York | Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| WO2014032019A2 (en) | 2012-08-23 | 2014-02-27 | Georgetown University | Compounds and methods of use thereof for treating tumors |
| US9676765B2 (en) | 2012-11-07 | 2017-06-13 | Karus Therapeutics Limited | Histone deacetylase inhibitors and their use in therapy |
| US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
| NZ714283A (en) | 2013-05-10 | 2020-04-24 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
-
2010
- 2010-01-26 EP EP10703334.2A patent/EP2391605B1/en not_active Not-in-force
- 2010-01-26 US US13/145,250 patent/US8748458B2/en not_active Expired - Fee Related
- 2010-01-26 MX MX2011007864A patent/MX2011007864A/es active IP Right Grant
- 2010-01-26 CA CA2750086A patent/CA2750086C/en not_active Expired - Fee Related
- 2010-01-26 CN CN201080009752.4A patent/CN102333761B/zh not_active Expired - Fee Related
- 2010-01-26 ES ES10703334.2T patent/ES2650810T3/es active Active
- 2010-01-26 CN CN201610083959.5A patent/CN105669540A/zh active Pending
- 2010-01-26 JP JP2011546968A patent/JP5597649B2/ja not_active Expired - Fee Related
- 2010-01-26 WO PCT/GB2010/050116 patent/WO2010086646A1/en not_active Ceased
-
2011
- 2011-07-21 IL IL214244A patent/IL214244A/en active IP Right Grant
-
2014
- 2014-04-30 US US14/266,197 patent/US9340503B2/en not_active Expired - Fee Related
- 2014-05-14 JP JP2014100193A patent/JP5981956B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014159475A5 (enExample) | ||
| JP6078639B2 (ja) | Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体 | |
| EP2152692B1 (en) | Compounds with anti-cancer activity | |
| JP2019517487A5 (enExample) | ||
| CA2957947A1 (en) | Compounds and methods for inhibiting histone demethylases | |
| JP2016525075A5 (enExample) | ||
| CN102333761B (zh) | Scriptaid电子等排体及其在治疗中的用途 | |
| JP2014506599A5 (enExample) | ||
| JP2015511217A5 (enExample) | ||
| CN110156785B (zh) | 吲唑类化合物及其制备方法和应用 | |
| JP2015516429A5 (enExample) | ||
| JP2017532358A5 (enExample) | ||
| JP2008515913A5 (enExample) | ||
| CA2774374A1 (en) | Substituted benzamide analogs as mglur5 negative allosteric modulators and methods of making and using the same | |
| JP2016531126A5 (enExample) | ||
| JP2016507575A5 (enExample) | ||
| JP2013544854A5 (enExample) | ||
| Kotb et al. | Design, synthesis, anticancer evaluation, and in silico ADMET analysis of novel thalidomide analogs as promising immunomodulatory agents | |
| JP2017532357A5 (enExample) | ||
| JP2015535273A5 (enExample) | ||
| JP2019526546A5 (enExample) | ||
| RU2015137972A (ru) | Новые производные дигидрохинолин-2-она в качестве ингибиторов альдостеронсинтазы (cyp1 1 b2 или cyp1 1 b1) | |
| RU2015145989A (ru) | Замещенное биарильное соединение | |
| JP2006519807A5 (enExample) | ||
| WO2014184235A1 (en) | Benzamide trpa1 antagonists |